Loading
A phase 2/3 trial of Progestins in Endometrial cancer, run by West China Second University Hospital, now recruiting.
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC is a phase 2/3 interventional study registered as NCT03463252 by West China Second University Hospital, with 224 participants planned, started 2018-04-01 and due to reach its primary completion in 2025-12-30. Interventions recorded: Progesterone, Mirena®, GnRH agonist. Conditions recorded: Endometrial Cancer, Atypical Endometrial Hyperplasia.
Linked to the drug Progestins because the registry names it among its interventions and Endometrial cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD), Endometrial cancer and the tag pipeline.
Shares Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD), Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Shares Endometrial cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/